- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01884246
Improving Heart Health in Appalachia (HeartHealth)
Reducing Health Disparities in Appalachians With Multiple Cardiovascular Disease Risk Factors
Individuals in Appalachian Kentucky are vulnerable to cardiovascular disease (CVD) by virtue of having high rates of multiple CVD risk factors. There is a critical need to develop and test CVD risk reducing interventions that are appropriate and effective in Appalachia. In the absence of such interventions, the dramatic CVD disparities seen in this area will continue to rise.
Lifestyle interventions reduce CVD risk by 44%. The investigators and others have demonstrated that lifestyle change is most effective when patients are given the tools to engage in effective self-care, and that interventions individualized to patients' specific needs and barriers are more effective than interventions that are not. The central hypothesis is that to be successful in Appalachia, CVD risk reducing interventions must focus on patient-centered lifestyle change that increase individuals' abilities to engage in self-care, must be culturally appropriate, and must have components that overcome barriers faced by individuals living in Appalachia.
The investigators propose a randomized, controlled comparative effectiveness trial with 300 individuals from Appalachian Kentucky who do not have a primary care provider and who are at risk for CVD by virtue of having two or more modifiable CVD risk factors. The investigators will compare (1) a patient-centered, culturally appropriate, self-care CVD risk reduction intervention (HeartHealth) designed to improve multiple CVD risk factors while overcoming barriers to success with (2) referral of patients to a primary care provider for management of their CVD risk factors. The investigators propose the following specific aims to be tested at 4 months and 1 year after baseline. To compare the short and long-term impact of the interventions on:
1) the risk factor selected by patients (i.e., tobacco use, blood pressure, lipid profile, hemoglobin-A1c (HgA1c) for diabetics, body mass index, waist circumference, depressive symptoms, or physical activity level); 2) all of the CVD risk factors of each patient; 3) quality of life; 4) patient and healthcare provider satisfaction; 5) desirability and adoptability by assessing adherence to recommended CVD risk reduction measures, and retention of recruited individuals. The investigators hypothesize that in comparison to the referral strategy, the multifaceted patient-centered, self-care intervention will engender more favorable outcomes across all measures.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40535
- University of Kentucky
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- residents of eastern Appalachian Kentucky
- do not have a primary care provider
at risk for CVD as reflected by having two or more of the following modifiable risk factors
- clinical diagnosis of hypertension or taking medications diagnosed for hypertension or found to be hypertensive on screening;
- clinical diagnosis of hyperlipidemia or taking medication for treating abnormal lipid levels, or any lipid abnormality found on screening that indicates hyperlipidemia;
- diagnosis of type 2 diabetes or HgA1c > 7% found on screening;
- overweight or obese (body mass index ≥ 25 kg/m2);
- waist circumference > 40 inches in men or > 35 inches in women;
- clinical diagnosis of depression, on medications for depression or found to have depressive symptoms (score of > 9 on the Patient Health Questionnaire-9) by baseline screening;
- sedentary lifestyle meaning that the individual does not engage in at least 30 minutes of moderate activity for at least 4 days per week
Exclusion Criteria:
- known coronary artery disease, cerebrovascular disease, history of acute coronary syndrome or peripheral arterial disease;
- taking medications (e.g., protease inhibitors) that interfere with lipid metabolism;
- cognitive impairment that precludes an individual from understanding the consent process, answering questionnaires, or participating in the intervention;
- chronic drug abuse;
- end-stage renal or liver or pulmonary disease;
- current active cancer (i.e., undergoing active treatment for cancer) other than isolated skin cancer treatable by simple excision;
- gastrointestinal disease that requires special diets (e.g., Crohn's disease; celiac disease)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Self-care CVD risk reduction
A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
|
A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
Other Names:
The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
|
ACTIVE_COMPARATOR: Referral to primary care provider
The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
|
The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cardiovascular risk factor selected by patient
Time Frame: 4 months
|
Patient selects their own risk reduction goal from the following: smoking, blood pressure, lipid profile, body mass index, hemoglobin-A1c for diabetics, depression, physical activity level, waist circumference |
4 months
|
cardiovascular risk factor selected by patient
Time Frame: 12 months
|
Patient selects their own risk reduction goal from the following: smoking, blood pressure, lipid profile, body mass index, hemoglobin-A1c for diabetics, depression, physical activity level, waist circumference |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
all CVD risk factors of each patient
Time Frame: 4 months
|
All CVD risk factors that each patient has are secondary outcomes
|
4 months
|
all CVD risk factors of each patient
Time Frame: 12 months
|
All CVD risk factors that each patient has are secondary outcomes
|
12 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
quality of life
Time Frame: 4 months
|
4 months
|
quality of life
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Debra K Moser, DNSc, RN, University of Kentucky
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCORI 3048110484
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on Self-care CVD risk reduction
-
Denver Health and Hospital AuthorityColorado Department of Public Health and EnvironmentCompleted
-
Mathematica Policy Research, Inc.RAND; Centers for Medicare and Medicaid ServicesUnknownCardiovascular Diseases
-
McGill UniversityPfizerCompletedHypertension | Obesity | Diabetes | Sedentary Lifestyle | Dyslipidemia | Cigarette SmokingCanada
-
Genomics PLCNHS North of England Commissioning Support (NECS)CompletedCardiovascular DiseasesUnited Kingdom
-
Baylor College of MedicineNational Institute of Mental Health (NIMH)Completed
-
Alar IrsTartu University Hospital; North Estonia Regional HospitalUnknownCardiovascular Diseases | Primary PreventionEstonia
-
UPecon Foundation, Inc.University of LausanneUnknownCardiovascular Diseases | Cardiovascular Risk FactorPhilippines
-
ViiV HealthcareCompletedHIV Infections | Infection, Human Immunodeficiency VirusChina
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Diseases | Hypertension | High Blood PressureGhana